BMO Capital initiates coverage on Zimmer Biomet with $95 target
BMO Capital analyst Vik Chopra has initiated coverage on Zimmer Biomet Holdings with a Market Perform rating and a price target of $95.
*this image is generated using AI for illustrative purposes only.
BMO Capital analyst Vik Chopra has initiated coverage on Zimmer Biomet Holdings with a Market Perform rating and a price target of $95. The rating provides a benchmark for the stock's performance relative to the broader market expectations.
Analyst Details
The coverage initiation was led by Vik Chopra of BMO Capital. The assessment categorizes Zimmer Biomet Holdings as a market performer, suggesting the stock is expected to perform in line with the market.
Price Target
BMO Capital has set a specific price objective for the company's shares.
| Metric | Value |
|---|---|
| Price Target | $95 |
What key factors could drive Zimmer Biomet's stock to outperform the $95 price target?
How might recent product launches or pipeline developments influence future analyst ratings?
What are the potential risks to Zimmer Biomet's market performance in the current economic climate?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
